Display options
Cite
Basutkar RS, Vinod CE, Saju SJ, et al. Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis. Ann Indian Acad Neurol. 2021;24(2):155-163doi: 10.4103/aian.AIAN_1223_20.
Basutkar, R. S., Vinod, C. E., Saju, S. J., Chebrolu, B., & Ponnusankar, S. (2021). Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis. Annals of Indian Academy of Neurology, 24(2), 155-163. https://doi.org/10.4103/aian.AIAN_1223_20
Basutkar, Roopa Satyanarayan, et al. "Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis." Annals of Indian Academy of Neurology vol. 24,2 (2021): 155-163. doi: https://doi.org/10.4103/aian.AIAN_1223_20
Basutkar RS, Vinod CE, Saju SJ, Chebrolu B, Ponnusankar S. Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis. Ann Indian Acad Neurol. 2021 Mar-Apr;24(2):155-163. doi: 10.4103/aian.AIAN_1223_20. Epub 2021 Apr 10. PMID: 34220057; PMCID: PMC8232512.
Copy Download .nbib Format: NLM
Share it on

Ann Indian Acad Neurol. 2021 Mar-Apr;24(2):155-163. doi: 10.4103/aian.AIAN_1223_20. Epub 2021 Apr 10.

Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis.

Annals of Indian Academy of Neurology

Roopa Satyanarayan Basutkar, Chris Elizabeth Vinod, Shruthi Jaya Saju, Bhavya Chebrolu, Sivasankaran Ponnusankar

Affiliations

  1. Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, India.

PMID: 34220057 PMCID: PMC8232512 DOI: 10.4103/aian.AIAN_1223_20

Abstract

BACKGROUND: The current target of migraine treatment is focused on Triptans. Lasmiditan, a non-vasoconstrictive and highly selective 5HT

OBJECTIVE: To identify an optimal dosing of Lasmiditan 100 mg versus 200 mg for the treatment of acute migraine attacks in adult patients with cardiovascular risk factors.

METHODS: Systematic searches were run in databases such as Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, Google scholar, and PUBMED. Out of 83 study records identified, two studies were included for quantitative analysis.

RESULTS: There was a significant headache pain freedom at 2 h [Odds Ratio (OR): 0.77; 95% Confidence interval (CI): 0.64-0.92] and sustained pain freedom at 24 h (OR): 0.75; 95% CI: 0.61-0.93] in patients taking Lasmiditan 200 mg compared to those taking Lasmiditan 100 mg. The results were statistically insignificant for parameters like most bothersome symptoms (MBS) free at 2 h, headache relief at 2 h, disability level at 2 h, and global impression of change at 2 h. A combined analysis of these parameters showed a remarkable difference between both the groups favoring Lasmiditan 200 mg [OR: 0.88; 95% CI: 0.81-0.95].

CONCLUSION: An oral dosing of Lasmiditan 200 mg is ideal for the treatment of acute migraine in adult patients with CV risk factors for attaining headache pain freedom at 2 h and sustained pain freedom at 24 compared to Lasmiditan 100 mg.

Copyright: © 2006 - 2021 Annals of Indian Academy of Neurology.

Keywords: Cardiovascular risk factors; Ditan; efficacy; lasmiditan; migraine; optimal dosing

Conflict of interest statement

There are no conflicts of interest.

References

  1. Cephalalgia. 2015 Feb;35(2):118-31 - PubMed
  2. Br J Clin Pharmacol. 2015 Aug;80(2):193-9 - PubMed
  3. Expert Opin Pharmacother. 2017 Sep;18(13):1409-1415 - PubMed
  4. Neurology. 2018 Dec 11;91(24):e2222-e2232 - PubMed
  5. Cephalalgia. 2020 Jan;40(1):19-27 - PubMed
  6. Expert Opin Drug Saf. 2003 Mar;2(2):123-32 - PubMed
  7. Cephalalgia. 1999 Mar;19(2):107-14; discussion 74 - PubMed
  8. Brain. 2019 Jul 1;142(7):1894-1904 - PubMed
  9. Cephalalgia. 2015 Mar;35(3):271-84 - PubMed
  10. Headache. 2004 May;44(5):414-25 - PubMed
  11. Expert Opin Pharmacother. 2020 Feb;21(2):147-153 - PubMed
  12. Pain Res Treat. 2016;2016:8538101 - PubMed
  13. Ann Neurosci. 2012 Apr;19(2):88-94 - PubMed
  14. Neurology. 2001;56(6 Suppl 1):S20-8 - PubMed
  15. Am J Med. 2002 Feb 1;112(2):135-40 - PubMed
  16. J Headache Pain. 2019 Aug 29;20(1):90 - PubMed
  17. Lancet Neurol. 2018 Nov;17(11):954-976 - PubMed
  18. Headache. 2015 Jan;55(1):3-20 - PubMed
  19. Headache. 2015 Jul-Aug;55 Suppl 4:221-35 - PubMed
  20. Continuum (Minneap Minn). 2015 Aug;21(4 Headache):953-72 - PubMed
  21. Lancet. 1979 Oct 27;2(8148):883-5 - PubMed
  22. Pharmacol Ther. 2018 Jun;186:88-97 - PubMed
  23. Headache. 2004 May;44(5):387-98 - PubMed
  24. Expert Rev Neurother. 2009 May;9(5):649-59 - PubMed
  25. Cephalalgia. 2013 Jul;33(9):629-808 - PubMed

Publication Types